Healthcare consumer and OTC brands company Haleon has hired Richard Manso as its new U.S. chief marketing officer.
His mission is to “evolve Hareon into a more agile and consumer-centric organization,” according to an April 27 statement.
The company sells a number of popular household brands, including Advil, Sensodyne, Tums and Theraflu, and has become more independent from pharmaceutical companies in recent years.
Haleon was once GSK’s consumer arm until the British drugmaker spun it off into a separate company in 2022. Pfizer then sold its remaining stake in the company in March 2025, a move that had been expected for years as the pharmaceutical industry as a whole began to exit OTC and consumer businesses.
In its fourth-quarter results released in February, the company reported organic revenue growth of 2.1%, slower than the previous quarter, and like other companies was hurt by a mild cold and flu season and weak U.S. consumer demand.
Last year, the company also launched its “Win as One” strategy, which aims to reach an additional 1 billion consumers by 2030 and “deliver industry-leading shareholder returns.”
Against this backdrop, Haleon is also looking to transform itself amid what the company calls “a profound transformation in consumer health,” where customers “increasingly expect seamless, personalized, and on-demand experiences.”
Haleon said Manso will be tasked with “building modern marketing capabilities across the company’s U.S. operations.”
This will allow him to focus on “priority areas” such as Medicare Advantage OTC, GLP-1 (where Haleon helps manage drug side effects), and emerging platforms such as women’s and children’s health.
“His role will also support Hareon’s broader ambitions to build a more connected, insight-driven marketing ecosystem that reflects how consumers engage with their health today,” the company added.
He recently joined Google to lead B2B marketing programs and help accelerate the adoption of data and AI-powered marketing projects.
